Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older.

Sydney GeorgeJustin CarricoKatherine A HicksDessi LoukovCheryl NgJessica ReganNikolaos Giannelos

Published in: PharmacoEconomics - open (2024)

RZV is expected to remain a cost-effective option for Canadian adults aged ≥50 years when using longer-term RZV efficacy and waning estimates, although the estimated public health impact was smaller than in the previous analysis (due to lower coverage/completion estimates).

Keyphrases

public health
physical activity
preterm infants
global health
middle aged
community dwelling
data analysis